A detailed history of Amalgamated Bank transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 4,523 shares of IBRX stock, worth $20,308. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,523
Previous 4,523 -0.0%
Holding current value
$20,308
Previous $29,000 41.38%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$3.23 - $6.17 $42,729 - $81,622
-13,229 Reduced 74.52%
4,523 $24,000
Q4 2023

Feb 06, 2024

BUY
$1.25 - $5.21 $3,982 - $16,599
3,186 Added 21.87%
17,752 $89,000
Q2 2023

Aug 11, 2023

BUY
$1.53 - $6.41 $5,794 - $24,274
3,787 Added 35.13%
14,566 $40,000
Q1 2023

May 02, 2023

SELL
$1.35 - $4.78 $2,376 - $8,412
-1,760 Reduced 14.04%
10,779 $20,000
Q3 2022

Nov 09, 2022

BUY
$3.65 - $6.43 $587 - $1,035
161 Added 1.3%
12,539 $62,000
Q2 2022

Aug 15, 2022

BUY
$2.68 - $6.14 $10,186 - $23,338
3,801 Added 44.32%
12,378 $46,000
Q1 2022

Jun 30, 2022

BUY
$5.05 - $7.53 $43,313 - $64,584
8,577 New
8,577 $48,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.8B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.